Skip to main content

Lichen Simplex Chronicus

1
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
3100%
+ 1 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Kamari Pharma
Kamari PharmaIsrael - Ness Ziona
1 program
1
IMP Application KM-001Phase 11 trial
Active Trials
NCT05454462Completed55Est. Apr 2023
Sanofi
SanofiPARIS, France
2 programs
DupilumabPHASE_3Monoclonal Antibody1 trial
DupilumabPHASE_3Monoclonal Antibody1 trial
Active Trials
NCT06687980Active Not Recruiting138Est. Aug 2026
NCT06687967Active Not Recruiting142Est. Aug 2026
Regeneron
RegeneronTARRYTOWN, NY
1 program
DupilumabPHASE_3Monoclonal Antibody

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
SanofiDupilumab
SanofiDupilumab
Kamari PharmaIMP Application KM-001

Clinical Trials (3)

Total enrollment: 335 patients across 3 trials

A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1)

Start: Nov 2024Est. completion: Aug 2026142 patients
Phase 3Active Not Recruiting

A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)

Start: Nov 2024Est. completion: Aug 2026138 patients
Phase 3Active Not Recruiting
NCT05454462Kamari PharmaIMP Application KM-001

KM-001 Cream for Treatment of Pruritus in Adult Patients With Lichen Simplex Chronicus (LSC)

Start: May 2022Est. completion: Apr 202355 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

Monoclonal Antibody is the dominant modality (100% of programs)
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.